The MSI state, characterized by defects in the expression of MMR-related proteins such as MLH1 and MSH2 is a significant factor contributing to the insensitivity of colorectal cancer to chemotherapeutic drugs37. This evidence concerns the gene MSH2 and colorectal cancer.